AI is changing clinical trial operations. What does that mean for your program timeline?
Most clinical organizations have completed the first wave of digital adoption. The harder question is what comes next – and whether AI can genuinely reduce the time and uncertainty that define complex trial execution.
Agentic AI in Clinical Trials: Where we are now and where we are going to be brings together PSI’s Head of Process Improvement, biopharma sponsors, and technology companies to examine how agentic AI is moving beyond task automation toward substantive process reengineering. The discussion will focus on where AI is delivering measurable results today – in site selection, startup, and operational decision-making – and where the field is realistically headed over the next three to five years.
Biopharma sponsors will share how their expectations of AI-enabled trial delivery are evolving, and what they need from their technology and CRO partners to translate that potential into on-time, on-budget execution.
If you are evaluating how AI fits into your development strategy for a complex or pivotal program, this session is a direct, evidence-grounded conversation with the people building and running these systems.
PANELISTS
- Kirill S. Soldatov, Head of Process Improvement, PSI — Moderator
- Dr Florian Maurer, Head of Clinical Development, Basilea Pharmaceutica
- Sezcan Ozturk, Head of Europe, Vice President, Luzsana Biotechnology
- Daniel Morris, Lead Solutions Engineer EMEA, Arango
- Dmytro Baikov, Vice President of AI, DataArt
